Page 11234..1020..»

Stem Cell Therapy helps dogs achieve better quality of life

September 18th, 2014 by jktkafvky No comments »

If your beloved pets can no longer play fetch because they suffer from chronic hip or back pain, then you might be interested in a stem cell procedure. Its minimally invasive and its growing in popularity in Central Pennsylvania.

Ben, the Akita, is undergoing stem cell surgery to reverse his chronic arthritis in his hip.

Veterinarian, Dr. Roger Horst, of Mercersburg Animal Clinic says, It just makes it more comfortable for them to be a pet, normal activity without to be on pain drugs.

Through a 30 minute surgery, Dr. Horst removes fatty tissue from Bens shoulder. He hands over the tissue to a lab technician. The technician, Delaney Kennedy, works with MediVet, a global leader in veterinary science.

Kennedy says, When we filter this tissue, everything stops at the top of the filtration and stem cells collect at the bottom. The stem cells are what we want and thats what we inject back into Ben.

Within 30 days, Bens quality of life will improve without the need for medicine.

Kennedy says, As pet owners maybe before could have put him down because hes in pain but now, were able to use stem cell therapy and help him live longer.

For more information contact Mercersburg Animal Clinic or MediVet.

See original here:
Stem Cell Therapy helps dogs achieve better quality of life

Medical Guidelines for Stem Cell Therapy in Australia – Video

September 18th, 2014 by DanielWZ No comments »



Medical Guidelines for Stem Cell Therapy in Australia
Dr Ralph Bright of Macquarie Stem Cells discusses the medical guidelines for practicing Stem Cell Therapy in Australia. http://www.macquariestemcells.com/ https://www.facebook.com/macquariestemcel…

By: Macquarie Stem Cells

Go here to read the rest:
Medical Guidelines for Stem Cell Therapy in Australia – Video

Stem cell harvesting methods used by Sydney doctor Ralph Bright untested by clinical trials

September 18th, 2014 by Famfari No comments »

ABC Ralph Bright harvests stem cells using the liposuction.

Serious questions have been raised about a stem cell doctor working in Western Sydney who charges $9,000 per procedure and uses methods that are untested by clinical trials.

An investigation by the ABC’s 7.30 program has revealed that Dr Ralph Bright bought his liposuction-based technology from an American company.

The US company is now the subject of a multi-million dollar fraud action, which has revealed the cells being marketed as live were in fact dead.

Dr Bright, of Macquarie Stem Cells, is a former GP and self-taught cosmetic surgeon.

He has been working with stem cells for four years, treating more than 400 patients, including the late model Charlotte Dawson, cricketer Geoff Lawson and Olympic volleyballer Kerri Pottharst.

Dr Bright has licensed his methods to other practitioners around the country and because they use the patients’ own cells he is not regulated by the Therapeutic Goods Administration (TGA).

Stem cells are often hailed as a miracle cure, but the nation’s top stem cell scientists are warning that buyers should beware of these sorts of procedures, which are yet to be subjected to clinical trials.

Professor of Stem Cell Science at the University of Melbourne, Martin Pera, said almost all stem cell therapy was experimental.

“Actually, this whole science of cell therapy is relatively new and it’s very, very important to understand that,” he said.

Continue reading here:
Stem cell harvesting methods used by Sydney doctor Ralph Bright untested by clinical trials

Regenerative Medicine Market (Bone and Joint) (By Technology – Stem Cell Therapy, Biomaterial and Tissue Engineering …

September 18th, 2014 by Walliec No comments »

LONDON, Sept. 17, 2014 /PRNewswire/ — U.S. National Institute of Health stated that regenerative medicine is the process of creating functional tissue to repair and replace tissue or organ which has lost …

See the original post:
Regenerative Medicine Market (Bone and Joint) (By Technology – Stem Cell Therapy, Biomaterial and Tissue Engineering …

Stem Cell Treatment for Multiple Sclerosis – Video

September 17th, 2014 by nRgrgISGwS No comments »



Stem Cell Treatment for Multiple Sclerosis
http://msrelief.com According to Dr. Balshi, multiple sclerosis is not a stem cell disease so the stem cells are not affected by MS. Stem cells can be harvested from the fat, activated with…

By: Choose JOY MS Relief

Continue reading here:
Stem Cell Treatment for Multiple Sclerosis – Video

Laminine Testimonials stroke – Video

September 16th, 2014 by twirtymut No comments »



Laminine Testimonials stroke
Laminine is availabe in the Philippines!!! “The Closest Alternative To Stem Cell Therapy…” “The miracle formula from a 9-day-old fertilized hen eggs” For More Info About Laminine, How a…

By: Karl Angelo Alipin

More here:
Laminine Testimonials stroke – Video

Laminine Testimonial-kidney failure – Video

September 16th, 2014 by Taimoorvh No comments »



Laminine Testimonial-kidney failure
Laminine is availabe in the Philippines!!! “The Closest Alternative To Stem Cell Therapy…” “The miracle formula from a 9-day-old fertilized hen eggs” For More Info About Laminine, How a…

By: Karl Angelo Alipin

Visit link:
Laminine Testimonial-kidney failure – Video

Trials and tribulations of stem cell therapy

September 16th, 2014 by alentiofalift No comments »

Edgar Irastorza was just 31 when his heart stopped beating in October 2008.

A Miami property manager, break-dancer and former high school wrestler, Irastorza had recently gained weight as his wife’s third pregnancy progressed. “I kind of got pregnant, too,” he said.

During a workout one day, he felt short of breath and insisted that friends rush him to the hospital. Minutes later, his pulse flatlined.

He survived the heart attack, but the scar tissue that resulted cut his heart’s pumping ability by a third. He couldn’t pick up his children. He couldn’t dance. He fell asleep every night wondering if he would wake up in the morning.

Desperation motivated Irastorza to volunteer for a highly unusual medical research trial: getting stem cells injected directly into his heart.

“I just trusted my doctors and the science behind it, and said, ‘This is my only chance,’” he said recently.

Over the past five years, by studying stem cells in lab dishes, test animals and intrepid patients like Irastorza, researchers have brought the vague, grandiose promises of stem cell therapies closer to reality.

Stem cells broke into the public consciousness in the early 1990s, alluring for their potential to help the body beat back diseases of degeneration like Alzheimer’s, and to grow new parts to treat conditions like spinal cord injuries.

Progress has been slow. The Michael J. Fox Foundation for Parkinson’s Research, an early supporter of stem cell research, pulled its financial backing two years ago, saying that it preferred to invest in research that was closer to providing immediate help for Parkinson’s disease patients.

But researchers have been slowly learning how to best use stem cells, what types to use and how to deliver them to the body – findings that are not singularly transformational, but progressive and pragmatic.

Here is the original post:
Trials and tribulations of stem cell therapy

Global And China Stem Cell Industry Size 2014 Market Analysis, Growth, Trends and Forecast 2017: MarketResearchReports …

September 16th, 2014 by SamQS No comments »

Albany, NY (PRWEB) September 15, 2014

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatment of cardiovascular diseases, leukemia (a kind of hematological system disease), nervous system diseases, damage or lesion of liver, kidney and other parenchymal organs, etc..

View Full Report at http://www.marketresearchreports.biz/analysis/223134

Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients.

Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/223134

The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. capital subsidy) and the capital support of significant cooperative partners, very few companies have dropped out.

Browse All Published Reports by Same Publisher at http://www.marketresearchreports.biz/publisher/67

Up to now, altogether 9 sorts of stem cell products have been approved worldwide, 3 of which are in the category of stem cell drugs developed by S. Korean companies, such as MEDIPOSTs adult stem cell drug CARTISTEM for osteoarthritis treatment and the stem cell product Prochymal (MEDIPOST obtained the product via acquiring the Therapeutics business of Osiris Therapeutics) direct at treating children suffering acute graft-versus-host disease (GVHD).

In the meantime, traditional pharmaceutical giants like Novartis are setting about quickly accessing the field through mergers and acquisitions. On Aug. 19, 2014, Novartis reached an acquisition agreement with Gamida Cell (a corporate dedicated to stem cell technology R&D and its application in stem cell transplantation for leukemia patients), which specified that Novartis spend USD35 million in acquiring 15% equity in the latter and win the option to take over the remaining equity in two years with USD165 million; in Sep. 2013, Novartis also entered a cooperation with Regenerex to jointly develop the hematopoietic stem cell platform FCRx of the latter.

Related Reports

Excerpt from:
Global And China Stem Cell Industry Size 2014 Market Analysis, Growth, Trends and Forecast 2017: MarketResearchReports …

Stem Cell Rejuvenation Center

September 14th, 2014 by DusEasennadew No comments »

Located in beautiful Phoenix, Arizona, we are the originalStem Cell Rejuvenation Center.We havebeenperformingstem cell therapies for over 10years and all of ourprocedures are done on site atour clinic herein Phoenix. Itis our top priority to provide you a safe, clean,sterile and friendly environment.Our Treatment Center is located just 8 minutes from the Phoenix Sky Harbor International Airport and many hotels provide shuttle service to and from our clinic making it ideal for out-of-town visitors. We provide stem cell therapy for a variety of conditions byusing our revolutionarytechnology and treatments to isolate and reinfuse stem cells from a patient’s own adipose stroma or fat (also called the Stromal Vascular Fraction (SVF)). We combine the best of technology, nature, and medicine to help improve the quality of our patients’ lives. Stem cell therapy is offered to those who are qualified candidates and whom desire treatment.

We are aStem Cell Therapy and Treatment Center, founded in the U.S.A., and performing all therapies within the United States. Neither our patients nor the stem cells that we harvest are transported outside the United States. We use less than minimally manipulated technology to provide Autologous Stem Cell and PRP therapies originally initiated during the 1990′s.

To see if you are a candidate, please fill-out this form and provide as much detail as possible.

Our Integrative staff and Physicians use a variety of modalities including Anti-aging and Eclectic medicine. These approaches are usedto treat many injuries and conditions. Below are some links toa journal database maintained by theNIH thatrelate to current research on stem cells and particular conditions……

Degenerative and Debilitating Conditions:

Autoimmune Conditions:

Viral Conditions:

More here:
Stem Cell Rejuvenation Center

Significant milestone in stem cell research at The Wellcome Trust – Medical Research Council institute

September 14th, 2014 by best registry cleaner No comments »

Comments(0)

Scientists are celebrating a breakthrough in stem cell research.

A type of human stem cell has been replicated in a lab for the first time in history.

The cells, previously impossible to duplicate, have been recreated to the equivalent of those between seven and nine days old the same as found in an embryo before it implants in the womb.

The creation of the human pluripotent cells opens a door for specialised cells to be created in the future for use in regenerative medicine.

The Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute led the research, which was carried out by both British and Japanese academics.

Professor Austin Smith, director, said: “Our findings suggest that it is possible to rewind the clock to achieve true ground state pluripotency in human cells.

“These cells may represent the real starting point for formation of tissues in the human embryo. We hope that in time they will allow us to unlock the fundamental biology of early development, which is impossible to study directly in people.”

The “reset” cells could be used as “raw material” for therapies, as well as diagnostic tools and drug screenings.

Scientists also hope that after further studying, the cells will help them learn more about how an embryo develops correctly, and how miscarriages and developmental disorders are caused.

Original post:
Significant milestone in stem cell research at The Wellcome Trust – Medical Research Council institute

Stem Cell Therapy for Osteoarthritis – Video

September 14th, 2014 by spitocuoupe No comments »



Stem Cell Therapy for Osteoarthritis
Ross Hauser, MD explains Stem Cell Prolotherapy using whole bone marrow. If you have osteoarthritis and are interested in how stem cell therapy may help you, we would love to see you in one…

By: Caring Medical and Rehabilitation Services

Link:
Stem Cell Therapy for Osteoarthritis – Video

Spinal cord injury – Case Study- Stem cell therapy- Giostar – Video

September 14th, 2014 by certified pharmacy technician No comments »



Spinal cord injury – Case Study- Stem cell therapy- Giostar
a brief introduction to Giostar and its Stem cell therapy Dr.Divyang Patel (MD) a spine surgeon at Giostar- INDIA, briefs about a case of cervical spine injury, which is also examined by a…

By: Devang Parmar

The rest is here:
Spinal cord injury – Case Study- Stem cell therapy- Giostar – Video

GIOSTAR- STEM CELL THERAPY & DR ANAND SHRIVASTAVA – Video

September 12th, 2014 by SSjdvmdvMSmXwAvnYC No comments »



GIOSTAR- STEM CELL THERAPY DR ANAND SHRIVASTAVA
Global Institute of Stem cell Therapy and Research – GIOSTAR Introduction to Stem Cell Therapy, and Dr.Anand Shrivastava – Chairman Co-founder of GIOSTAR.

By: Devang Parmar

See the original post here:
GIOSTAR- STEM CELL THERAPY & DR ANAND SHRIVASTAVA – Video

Woman Receives First Stem Cell Therapy Using Her Own Skin Cells

September 12th, 2014 by Ninjandi No comments »

A Japanese woman is the first to receive retinal cells made from her own skin cells

The rest is here:
Woman Receives First Stem Cell Therapy Using Her Own Skin Cells

Stem cell therapy | Stem cell treatment and medicine …

September 11th, 2014 by kellytrumps No comments »

Prof. Alexander Smikodub

MD Ph.D

Alexander Smikodub jr.

MD Ph.D

Our clinic offers the advanced and patented methods of fetal stem cell treatment for various conditions and diseases. This method of treatment can be found in wikipedia: Stem cell therapy. Fetal stem cells are non-specialized cells that differentiate (turn) into any other cell type of the body that form organs and tissues. Fetal stem cells that we use for treatment have huge potential for growth, differentiation and are not rejected by the patients body, which allows to achieve unique long-term clinical effects.

We have more than 15 years of experience in stem cell therapy and are the leaders of the industry. Most of the methodic used in the clinic are unique and patent protected in many countries including USA. Since 1994 prof. Alexander Smikodub Sr. was the main researcher, doctor and administrator of the clinic. Now his son, Alexander Smikodub Jr. M.D. continues his fathers venture. During these years more than 6500 patients from all over the world received fetal stem cell treatment, resulting in significant improvement of their conditions, and in case of timely contact with us in complete cure of the diseases still considered lethal by most medical institutions.

Read more…

Stem cells are the new word in the medical science, possibly the new revolution. Their importance can be compared with antibiotics discovery or the first successful heart transplantation. They are the inner restorative and regenerative reserve of your body, found in blood, fat layer and bone marrow. After injection of a big stem cells doze, impaired tissues are recovered, regeneration speed is increased and overall condition is greatly improved. We use only material from healthy patients, which passes multiple security checks. They are a perfect material for treating a wide variety of neural and physical diseases.

Continue reading here:
Stem cell therapy | Stem cell treatment and medicine …

Regenerative Medicine Foundation (RMF) is New Organizer of 2014 World Stem Cell Summit #WSCS14 in San Antonio, TX.

September 11th, 2014 by marcyloisa No comments »

SAN ANTONIO — Genetics Policy Institute (GPI), the producer of the annual World Stem Cell Summit, and the Regenerative Medicine Foundation (RMF), organizers of the annual RegMed Conference and sponsor …

Read more:
Regenerative Medicine Foundation (RMF) is New Organizer of 2014 World Stem Cell Summit #WSCS14 in San Antonio, TX.

Publisher launches new book to bring awareness to debate surrounding stem cell research

September 11th, 2014 by NakieBpy9 No comments »

Mary Ann Liebert, Inc., leading publisher of over 80 science, technology, and medical publications, announced today the launch of first time hard cover title Inevitable Collision: The Inspiring Story that Brought Stem Cell Research to Conservative America, in an effort to bring awareness to the growing conversation and debate surrounding stem cell research and regenerative medicine.

Written by Tory Williams, author, advocate, mom, and co-founder of the Alabama Institute of Medicine (AIM), Inevitable Collision is a human-interest story that details the controversial Geron Trial, the first human embryonic stem cell trial for patients with paralysis, and thoughtfully documents the first and fifth patients, TJ Atchison and Katie Sharify. The book features provocative conversations with doctors, medical researchers, and scientists including Dr. Hans Keirstead, the famous scientist whose groundbreaking research helped rats to overcome paralysis through stem cell treatments and introduced the therapy to humans, and helps inform the public conversation by presenting the facts and opportunities surrounding stem cell research and therapy.

“Tory’s personal journey of advocacy, perseverance, and commitment to the advance-ment of stem cell research and its application is an important and relevant testament to the stem cell conversation at large,” said Mary Ann Liebert, president and CEO of the company that bears her name. “Inevitable Collision will strongly resonate with the six million Americans suffering from paralysis, a quarter of which are the result of a spinal cord injury. In a very readable and compelling style, Williams has brought the much needed human voice to the oftentimes controversial and misunderstood topic of stem cell technology. It is an important read for the public, legislators, and patients and their families, as well as for researchers and members of the health care community. This book will make a difference!”

Compared to the narrative and journalistic writing style of The Immortal Life of Henrietta Lacks, Inevitable Collision explains in reader-friendly terms how stem cells work, and why they are considered important tools in finding a cure for paralysis and other disabilities. The book also details author Tory Williams’ physical and emotional struggles while raising funding and public awareness surrounding embryonic stem cell research across the nation.

“Through this book I hope to bridge the gap between science and religion and raise awareness of the importance and power of stem cell research,” said Tory Williams. “This book is intended not only for patients who suffer from paralysis and diseases such as cancer and Parkinson’s, but for everyone affected by these afflictions, directly and indirectly.”

The launch comes on the heels of the California Institute for Regenerative Medicine’s (CIRM) recent announcement green lighting the follow-up phase to the Geron clinical trial as approved by the FDA.

Inevitable Collision’s 208 pages plus 8-page photo spread retails at $21.95 for the hard-back and $9.99 for the e-book and includes an afterword written by Roman Reed, a tire-less patient advocate who was paralyzed from a sports injury 20 years ago. Roman is the Founder of the Roman Reed Foundation and Roman’s Law, which was the impetus for California’s groundbreaking stem cell program.

Excerpt from:
Publisher launches new book to bring awareness to debate surrounding stem cell research

Clinical Trial to Test Safety of Stem Cell-Derived Therapy for Type 1 Diabetes

September 11th, 2014 by Excarcefuff No comments »

Contact Information

Available for logged-in reporters only

Newswise Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc., a San Diego-based biotechnology firm specializing in regenerative medicine, have launched the first-ever human Phase I/II clinical trial of a stem cell-derived therapy for patients with Type 1 diabetes.

The trial will assess the safety and efficacy of a new investigational drug called VC-01, which was recently approved for testing by the U.S. Food and Drug Administration. The 2-year trial will involve four to six testing sites, the first being at UC San Diego, and will recruit approximately 40 study participants.

The goal, first and foremost, of this unprecedented human trial is to evaluate the safety, tolerability and efficacy of various doses of VC-01 among patients with type 1 diabetes mellitus, said principal investigator Robert R. Henry, MD, professor of medicine in the Division of Endocrinology and Metabolism at UC San Diego and chief of the Section of Endocrinology, Metabolism & Diabetes at the Veterans Affairs San Diego Healthcare System. We will be implanting specially encapsulated stem cell-derived cells under the skin of patients where its believed they will mature into pancreatic beta cells able to produce a continuous supply of needed insulin. Previous tests in animals showed promising results. We now need to determine that this approach is safe in people.

Development and testing of VC-01 is funded, in part, by the California Institute for Regenerative Medicine, the states stem cell agency, the UC San Diego Sanford Stem Cell Clinical Center and JDRF, the leading research and advocacy organization funding type 1 diabetes research.

Type 1 diabetes mellitus is a life-threatening chronic condition in which the pancreas produces little or no insulin, a hormone needed to allow glucose to enter cells to produce energy. It is typically diagnosed during childhood or adolescence, though it can also begin in adults. Though far less common than Type 2 diabetes, which occurs when the body becomes resistant to insulin, Type 1 may affect up to 3 million Americans, according to the JDRF. Among Americans age 20 and younger, prevalence rose 23 percent between 2000 and 2009 and continues to rise. Currently, there is no cure. Standard treatment involves daily injections of insulin and rigorous management of diet and lifestyle.

Phase I/II clinical trials are designed to assess basic safety and efficacy of therapies never before tested in humans, uncovering unforeseen risks or complications. Unpredictable outcomes are possible. Such testing is essential to ensure that the new therapy is developed responsibly with appropriate management of risks that all medical treatments may present.

This is not yet a cure for diabetes, said Henry. The hope, nonetheless, is that this approach will ultimately transform the way individuals with Type 1 diabetes manage their disease by providing an alternative source of insulin-producing cells, potentially freeing them from daily insulin injections or external pumps.

This clinical trial at UC San Diego Health System was launched and supported by the UC San Diego Sanford Stem Cell Clinical Center. The Center was recently created to advance leading-edge stem cell medicine and science, protect and counsel patients, and accelerate innovative stem cell research into patient diagnostics and therapy.

Read more here:
Clinical Trial to Test Safety of Stem Cell-Derived Therapy for Type 1 Diabetes

ViaCyte, Inc. Awarded $16.6 Million Accelerated Development Pathway Grant from CIRM to Expand Clinical Development of …

September 11th, 2014 by tiegrania No comments »

SAN DIEGO, Sept. 10, 2014 /PRNewswire/ –ViaCyte, Inc., a privately held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of diabetes, called VC-01, announced today that it has been selected to receive a $16.6 million Accelerated Development Pathway Award from the California Institute for Regenerative Medicine (CIRM). According to CIRM …

Go here to see the original:
ViaCyte, Inc. Awarded $16.6 Million Accelerated Development Pathway Grant from CIRM to Expand Clinical Development of …